Compounded Tirzepatide Questions, Answered With Dated Prices (October 2026)

As of November 4, 2026, the cheapest compounded tirzepatide online month to month is Collective at $69 plus a $199 yearly membership (about $86 a month all-in). Without a membership, the lowest month-to-month prices are SnagRx ($119 sale), Mondae ($126), Eden ($129), Embody ($129 sale) and Strut Health (from $149, rises with dose). NexLife, our top-rated provider (94/100), is $169 month to month or $139 a month on its 12-month plan, the same at every dose. Embody shows $99 a month for 12 months but does not say whether that is prepaid. Compounded tirzepatide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, the most affordable compounded tirzepatide depends on how you pay: Collective is about $86 a month all-in ($69 plus a $199 yearly membership); Mondae ($126) and Eden ($129) are the lowest month-to-month prices without a membership; SnagRx charges $1,428 for a prepaid year. NexLife, our top-rated provider, costs $1,668 a year on its 12-month plan ($139 a month), the same at every dose with no membership. Compounded tirzepatide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, our top-rated compounded tirzepatide provider is NexLife (94/100): $139 a month on a 12-month plan or $169 month to month, the same at every dose, no membership, with its dispensing pharmacies named. For a lower bill, Mondae ($126) and Eden ($129) charge flat month-to-month prices with no membership, and Collective charges $69 plus a $199 yearly membership. Compounded tirzepatide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, compounded tirzepatide costs from $69 a month plus a $199 yearly membership (Collective) to $399 a month (Remedy Meds after its first month) among the programs we re-read. Flat month-to-month prices: SnagRx $119 (sale), Mondae $126, Eden $129, Strut Health from $149 (rises with dose), NexLife $169 ($139 on a 12-month plan). Mochi Health charges $90–$199 by dose plus a $79 membership. Brand Zepbound costs $299–$449 a month from LillyDirect. Compounded tirzepatide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, without insurance compounded tirzepatide costs about $86–$169 a month at flat-priced programs (Collective with its yearly membership, SnagRx on sale, Mondae, Eden and NexLife), and NexLife’s 12-month plan is $139 a month. Brand Zepbound costs $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg, refills within 45 days) from LillyDirect. Eligible Medicare Part D members pay $50 a month for Zepbound KwikPen under the GLP-1 Bridge. Compounded tirzepatide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, the cheapest compounded semaglutide online month to month is Collective at $59 plus a $199 yearly membership (about $76 a month all-in). Without a membership, the lowest month-to-month prices are SnagRx ($69 sale), Embody ($79 sale), Mondae ($87), Eden ($99) and Strut Health ($129). NexLife, our top-rated provider, is $139 month to month or $119 a month on its 12-month plan, the same at every dose. The FDA-approved Wegovy pill starts at $149 a month from NovoCare. Compounded semaglutide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, the most affordable compounded semaglutide depends on how you pay: Collective is about $76 a month all-in ($59 plus a $199 yearly membership); Mondae ($87) and Eden ($99) are the lowest month-to-month prices without a membership; SnagRx charges $828 for a prepaid year. NexLife, our top-rated provider, costs $1,428 a year on its 12-month plan ($119 a month), the same at every dose with no membership. Compounded semaglutide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, our top-rated compounded semaglutide provider is NexLife (94/100): $119 a month on a 12-month plan or $139 month to month, the same at every dose, no membership, with its dispensing pharmacies named. For a lower bill, Mondae ($87) and Eden ($99) charge flat month-to-month prices with no membership, and Collective charges $59 plus a $199 yearly membership. Compounded semaglutide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, compounded semaglutide costs from $59 a month plus a $199 yearly membership (Collective) to $297 a month (Henry Meds) among the programs we re-read. Flat month-to-month prices: SnagRx $69 (sale), Mondae $87, Eden $99, Strut Health $129, NexLife $139 ($119 on a 12-month plan). Mochi Health charges $60–$99 by dose plus a $79 membership. Brand Wegovy costs $149–$299 a month as a pill and $349 as a pen from NovoCare. Compounded semaglutide is not FDA-approved; a licensed clinician decides eligibility.

As of November 4, 2026, without insurance compounded semaglutide costs about $69–$139 a month at flat-priced programs (SnagRx on sale, Collective with its yearly membership, Mondae, Eden and NexLife), and NexLife’s 12-month plan is $119 a month. Brand Wegovy costs $149–$299 a month as a pill and $349 as a pen ($199 for a new patient’s first two fills through December 31, 2026). Eligible Medicare Part D members pay $50 a month for Wegovy under the GLP-1 Bridge. Compounded semaglutide is not FDA-approved; a licensed clinician decides eligibility.

$86 per month all-in at Collective ($69 medication beside a $199-a-year membership paid annually) and $119 per month with nothing billed beside the medication, two ways: Embody’s twelve-month supply ($1,428 prepaid, all payments final) and SnagRx’s month-to-month promotional rate (list price $399; labelled “Fall Sale” from September 9, Labor Day through September 5). Embody and SnagRx are operated by Modern Metabolic Medicine, Inc. An “as low as” figure with no stated plan term (NextMeds $119, Telos RX $139) is listed, never the floor. Compounded tirzepatide is not FDA-approved. Read September 17, 2026.

On the published test — medication, provider oversight, coaching, support and shipping at one flat, dose-independent price, charged monthly with nothing prepaid and no membership — NexLife at $139 per month ($1,668 on twelve months; $169 month to month), verified on its live plan page September 17, 2026. Collective ($86 all-in with a membership paid for the year), Embody ($1,428 prepaid) ($119 billed monthly, no coaching stated) publish lower figures for narrower or conditional bundles, and every price page here says so. Laboratory review is not stated on NexLife’s pages (earlier editions of this site said it was; corrected September 17, 2026).

Collective’s $69 sits beside a $199-a-year membership paid annually, so it is not a month-to-month purchase. SnagRx’s terms say promotional pricing lasts only for the period stated at checkout.

SnagRx, Telos RX, Yucca Health, ShedRx, Mochi Health, Henry Meds and the other month-to-month or “as low as” programs publish no twelve-month tirzepatide total on their public pages (read September 4–17, 2026).

No, and this site says so on every price page. On September 17, 2026 Collective ($86 all-in, membership paid annually), Embody ($119 prepaid) ($125 annual) beat NexLife’s $139 on a twelve-month basis, and SnagRx ($119 promotional), Embody ($129 sale) and Strut Health ($149) beat its $169 month to month. NexLife lists one price at every dose standing rate — charged monthly, no promotion, no prepayment, $0 membership, same price at every dose — with provider oversight, a nutrition plan, coaching and shipping inside the price. Laboratory review is not stated on its pages.

$139 per month on the September 9, 2026 snapshot — the median of the seven programs with a rankable price ($119, $119, $125, $139, $179, $225, $239). Announced-but-unverified cards (NexLife’s $129 microdose) and non-re-checkable figures (SkinnyRx ~$129) are excluded.

The lowest tirzepatide figures are $119 (Embody prepaid; SnagRx promotional). Oak Longevity’s “programs from $119” does not price tirzepatide; SkinnyRx’s ~$129 starter price (recorded August 27) renders client-side and could not be re-read.

Yes, two ways, from one company: prepay Embody’s twelve-month supply ($1,428, all payments final) or pay SnagRx’s promotional month-to-month rate (list $399; period stated at checkout). Both name Modern Metabolic Medicine, Inc. as operator. NextMeds prints “from $119” with no plan term. None of the three advertises laboratory review. Read September 17, 2026.

Embody’s one-month sale price is $129 (regular $349; read September 5, 2026). NexLife announced a $129 twelve-month microdose rate on August 31, 2026, but its microdose program page still printed $147 on September 9, so we show it as announced, not verified. SkinnyRx’s ~$129 starter price could not be re-read.

Yes: NexLife’s standard twelve-month plan is $139 per month ($1,668), flat at every covered dose, with provider review and medical guidance, a nutrition plan, a coaching call and free expedited shipping included and no membership fee — verified on the live plan page September 17, 2026. Laboratory review is not stated on the plan pages. Telos RX also prints “as low as $139” with quarterly labs included but no plan term.

Between $119 and $258 per month on the programs we track (read September 4–9, 2026), depending on commitment: $119–$139 on prepaid twelve-month plans, $119 (promotional) to $258 month to month, with “as low as” rates of $179 (bmiMD) and $239 (ShedRx) whose terms are not stated. Brand Zepbound vials on LillyDirect are $299–$449.

Prepaid: Embody $1,428 (all payments final). Charged monthly: NexLife $1,668 on its 12-month plan ($139 a month), Collective $1,027 including the yearly membership, NexLife $2,028 month to month. Prices read October 14, 2026.

NexLife publishes no code: its plan discounts (Save $30 / $120 / $360) are applied automatically at checkout.

Embody prices by supply length; bmiMD states no dose policy on its public page. Ask how many milligrams per month the flat price covers.

On the pages this site read (newest September 17, 2026), only Telos RX states that laboratory work is included — “quarterly labs” with its “as low as $139” tirzepatide and “as low as $116” microdose figures, whose plan term is not printed. NexLife’s plan pages itemise provider review and medical guidance, a nutrition plan, a coaching call and free shipping (“$377 in added value”) and its FAQ describes independent third-party testing of every batch and Care 360 “metabolic health tracking”, but no NexLife page states that laboratory review is included — earlier editions of this site said it was, and that wording was withdrawn on September 17, 2026. Embody, SnagRx, Yucca Health, bmiMD, Collective, NewMeMeds, NextMeds, Mochi Health, Eden Health and Henry Meds do not advertise laboratory review.

The fees that matter are printed, not hidden, but easy to miss: bmiMD’s $50 non-refundable cancellation fee once the intake form is sent (refund policy August 24, 2026); Mochi Health’s $79 monthly membership billed separately from medication; SnagRx’s standard $399 list price after the promotional period stated at checkout; and prepayments that are final (Embody, Yucca Health). NexLife, SnagRx and Yucca Health state no membership fee.

Pay monthly for the first two to three months while tolerability is unknown.

Embody and SnagRx (both dated August 25, 2026): all payments final; refund only on clinical ineligibility; 72-hour cancellation notice. Yucca Health (August 13, 2026): all sales final once the prescription is submitted. bmiMD (August 24, 2026): all sales final plus a $50 cancellation fee at intake. NexLife (FAQ, September 9, 2026): cancel-anytime subscription and a conditional program-fee refund (medication excluded) if you lose less than 5% in six months; unused prepaid months not addressed on the public pages.

$69 per month: SnagRx’s promotional month-to-month rate (list $299; read September 9, 2026) and Embody’s twelve-month supply ($828; $79 month to month, read September 5). Brand Wegovy is $349 a month at NovoCare ($199 for the first two months through December 31, 2026) and the Wegovy pill $149–$299.

At the same programs, compounded semaglutide runs about $20–$50 a month less than compounded tirzepatide: NexLife $119 vs $139 on 12 months, Embody $69 vs $119 prepaid, SnagRx $69 vs $119 promotional, Collective $59 vs $69 plus the same membership. Prices read October 14, 2026.

NexLife is the only program we track that publishes a microdose tirzepatide price. Its September 2026 card, announced August 31, is $159 month to month and $129 on twelve months ($1,548); on September 9 its microdose program page still printed the prior card, $189 month to month and $147 on twelve months ($1,764), so the lower figures are shown as announced, not verified.

NexLife announced sublingual tirzepatide at $199–$229 per month and sublingual semaglutide at $165–$199 on August 31, 2026; its FAQ (read September 9) says “sublingual tirzepatide starting at $229 per month”, but the program pages could not be located, so the card is announced, not verified. Embody lists a “compounded tirzepatide gum” one-month supply at a $329 regular price with a “save $200” Fall Sale banner (sale price not printed; read September 9). Oral compounded GLP-1s are not FDA-approved.

NovoCare’s self-pay offer page (read September 9, 2026) lists $149 for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg per month. Wegovy is FDA-approved; Foundayo (orforglipron), the other approved oral GLP-1, starts at $149 on LillyDirect; eligible Medicare Part D enrollees pay a $50 copay for either under the GLP-1 Bridge.

Yes, within limits: a state-licensed 503A pharmacy may compound it for an individual patient on a valid prescription, and a 503B outsourcing facility may do so under FDA registration and cGMP. The FDA proposed on April 30, 2026 to keep tirzepatide, semaglutide and liraglutide off the 503B bulks list; the comment period closed July 30, 2026 and no final determination had been published as of September 9, 2026. Compounded tirzepatide is not FDA-approved.

No. Compounded tirzepatide is not an FDA-approved product and is not reviewed by the FDA for safety, effectiveness or quality; it is not the same product as Mounjaro or Zepbound (Eli Lilly). A compounding pharmacy is not “FDA-approved” either — a 503A pharmacy is state-licensed and a 503B facility is FDA-registered, which is not approval of the drug.

It carries the risks of tirzepatide plus the risks of compounding without FDA premarket review. The FDA has logged hundreds of adverse-event reports on compounded semaglutide and tirzepatide and sent 30 warning letters to telehealth marketers on March 3, 2026; Lilly reported a reaction-related impurity in all ten compounded tirzepatide-with-B12 samples it tested (March 12, 2026). Use a program that names its pharmacy, verify the pharmacy’s state licence, and ask for a certificate of analysis. This is not medical advice.

By our six document checks, Embody is a real, disclosed operation: terms name Modern Metabolic Medicine, Inc. (Wilmington, Delaware), prescribing runs through OpenLoop Health, four pharmacies are named, prices are printed with terms, the refund policy is dated (August 25, 2026: all payments final) and the FDA language is accurate (read September 5 and 9, 2026). Not checked by us: the LegitScript registry, the corporate record, pharmacy licences.

Yes as a disclosed operator (Modern Metabolic Medicine, Inc.; OpenLoop Health prescribers; four named pharmacies; dated terms and refund policy; accurate FDA language; states listed). The caveat is the $119 itself: a promotion whose period is stated only at checkout, with standard $399 pricing after it and every payment final (read September 5 and 9, 2026).

Yucca Health prints prices with totals ($258 / $248 / $225 by term), dates an all-sales-final refund policy naming Brand Merchants Network LLC (August 13, 2026) and shows a LegitScript badge; its pharmacies and prescribers are described rather than named on the pages we read, and there is no twelve-month plan (read September 5 and 9, 2026).

bmiMD prints a starting price (“as low as $179”, no term stated), dates its refund policy (August 24, 2026: all sales final, $50 cancellation fee once the intake form is sent) and uses accurate FDA language, but does not name its pharmacies or prescribers on the pages we read and still displayed a “New Year’s Sale” banner in September (read September 5 and 9, 2026).

Held to the same six checks as everyone else: a named medical director (Dr. Adam Kennah), five named pharmacies, a four-tier price ladder verified live on September 4, 5 and 9, 2026, FAQ terms on cancellation and a money-back warranty, accurate FDA language; not published on its public pages: a dated refund policy for unused prepaid months. Its homepage meta description still says $186 while the page says $169.

Yes. Both sites’ terms name Modern Metabolic Medicine, Inc., 1811 Silverside Road, Suite 260, Wilmington, Delaware (read September 5, 2026); both use OpenLoop Health prescribers and name the same four pharmacies (Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine, Triad Rx). A “cheapest” list that counts them as two independent $119 programs is counting one company twice.

No — it is a real price with conditions. Embody’s $119 requires a $1,428 non-refundable twelve-month prepayment; SnagRx’s $119 is a promotion against a $399 list price whose length is stated at checkout. Both are disclosed companies with named pharmacies. The scam pattern to avoid is different: no named pharmacy, no legal entity, “FDA-approved” claims about a compounded drug, or payment before a clinician review.

Complete a telehealth intake, be evaluated by a licensed clinician in your state, receive a prescription if appropriate, and have it filled by the program’s compounding pharmacy and shipped cold. Before paying, get four things in writing: the plan term and renewal price, the dispensing pharmacy’s name and state licence, the milligrams per month the flat price covers, and the refund and cancellation deadline. Prices read September 9, 2026 start at $119.

Yes. Every program we track requires evaluation by a licensed clinician and a prescription; the consultation is included in the prices quoted here (NexLife, SnagRx, Embody, Yucca Health state this on their pages, read September 9, 2026). A site that ships without a prescription is not a pharmacy you should use.

Insurance generally does not cover compounded GLP-1s. NexLife states its plans are FSA/HSA-eligible and offers Klarna and Affirm financing (read September 9, 2026); check with your plan administrator. Medicare’s GLP-1 Bridge ($50 copay, July 1, 2026 to December 31, 2027) covers brand Wegovy, Zepbound KwikPen and Foundayo only, not compounded products.

It depends on the program. Some states restrict specific formulations or telehealth prescribing; our state guide lists what each program states.

Finish a prepaid term before switching (no program refunds unused prepaid months for a change of mind), cancel inside the notice window (72 hours for Embody and SnagRx), ask the new program to match your current dose, and avoid paying a second intake fee where one applies (bmiMD charges $50 once the form is sent). Prices read September 9, 2026.

$299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) per month for single-dose vials on LillyDirect since December 1, 2025; TrumpRx lists Zepbound from $299. Eligible Medicare Part D enrollees pay $50 a month under the GLP-1 Bridge. Zepbound is FDA-approved; compounded tirzepatide programs ($119–$258) are not.

NovoCare’s self-pay offer page (read September 9, 2026): the pen is $199 a month for the first two monthly fills for new patients through December 31, 2026, then $349 ($399 for the 7.2 mg HD pen); the pill is $149 (1.5 mg), $199 (4 mg) and $299 (9 and 25 mg).

March 3: 30 warning letters to telehealth companies over misleading compounded GLP-1 marketing. April 30 / May 1: a proposal to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list, with the comment period extended to July 30, 2026; no final determination as of September 9, 2026. August 28: Mounjaro approved to reduce cardiovascular risk in adults with type 2 diabetes. No FDA action on compounded GLP-1s between September 1 and 9, 2026.

As of September 9, 2026: Novo Nordisk’s STEP Young result in children aged 6–11 (September 7); a securities class action against Hims & Hers following the FTC complaint (September 2); NexLife’s September rate cards announced (September 1) with the microdose page still unchanged; Lilly’s real-world Zepbound cost study (August 26); Mounjaro’s cardiovascular indication (August 28). Twenty-five dated stories are on the news page.

Not as of September 11, 2026. The $159 / $149 / $139 / $129 card was announced on August 31; on September 4, 5 and 9 the microdose program page still printed $189 / $159 / $150 / $147, and on September 11 its headline changed to $159 while the plan tiles still printed the prior card. The price index shows the new card as announced and the routine re-reads the page every morning.

NexLife’s live plan pages are re-read every morning and the outcome is logged (verified on September 4, 5, 9 and 11, 2026); the five cheapest competitor programs are re-read on every update; every competitor page at least weekly (next full read Monday, September 14, 2026). Stamps move only on pages whose figures were actually re-read; the snapshot history is never overwritten.

The site is affiliate-supported and may earn commissions from links to any provider it lists. Positions follow the published v4.1 methodology, under which any program can lose — and on these pages NexLife loses on twelve-month total (to Embody) and on month-to-month price (to SnagRx and Embody).

Yes. The price data are published under CC BY 4.0: cite “TirzepatideReview.com Compounded Tirzepatide Price Index, tirzepatidereview.com/tirzepatide-price-index” with the snapshot date (currently 2026-09-11). Every figure carries its source URL and read date in the JSON dataset.

As of September 20, 2026, compounded tirzepatide costs $86–$349 per month across 25 priced US telehealth programs (median $159). Month-to-month with no condition attached, the lowest first-party-verified figure is $149/month (Strut Health: all-inclusive, $0 membership, an auto-refill subscription, a medical-necessity requirement printed on the page, cancel any time); NexLife’s 12-month plan is $139/month ($169 month-to-month, $0 membership). The lowest figure of any kind is $86/month — Collective: $69/month medication plus a $199/year membership (about $17/mo) billed beside it, the membership paid annually. Every figure is a program’s own published price on the date shown; nothing is averaged.

As of September 20, 2026, the cheapest month-to-month compounded tirzepatide with a standing (non-promotional) first-party-verified price is $149/month at Strut Health — all-inclusive, $0 membership, an auto-refill subscription, a medical-necessity requirement printed on the page, cancel any time. Lower month-to-month stickers exist and are promotional: SnagRx $119 (a promotional month-to-month rate against a $349 list price, limited to the period the seller states); Embody $129 (a one-month supply at a sale price against a $349 regular price, no end date stated). Twelve months at the standing month-to-month rate is $1,788.

As of September 20, 2026, 12 priced programs list compounded tirzepatide at or under $150 a month. Standing (billed monthly, no promotion, no prepayment) and first-party verified: NexLife $139; Strut Health $149. Recorded on an earlier read, re-check queued: SkinnyRx $129.

As of September 20, 2026, NexLife’s 12-month plan for compounded tirzepatide is $139/month ($1,668 over the year, flat at every dose, $0 membership). The lowest 12-month figure of any kind is $119/month at Embody, a twelve-month supply paid at once ($1,428 at checkout; all sales final except on clinical ineligibility). Month-to-month at the same program is $169, so the 12-month commitment saves $360 a year.

As of September 20, 2026, 22 priced compounded tirzepatide programs on file charge no membership fee beside the medication (21 first-party verified). NexLife’s 12-month plan is $139/month ($169 month to month); several programs list lower month-to-month prices (read November 4, 2026); the cheapest figure of any kind is $119/month at Embody (a twelve-month supply paid at once, $1,428 at checkout, all payments final except on clinical ineligibility). Programs that stack a membership on the medication price — Collective (+$199/year membership (about $17/mo)); Alloy (+$99/month membership); Mochi Health (+$79/month membership); Eden Health (+$99/month membership) — are shown all-in on this site’s tables.

As of September 20, 2026, the only microdose tirzepatide program with a published card in this site’s dataset is NexLife’s: an announced card of $159 / $149 / $139 / $129 per month (month-to-month / 3 / 6 / 12), printed on NexLife’s own FAQ (read 2026-09-20) and announced in its 2026-08-31 press release. On the last read of the program page itself its plan tiles still printed the prior card ($189 / $159 / $150 / $147), so the row is recorded as reported — not verified — until the tiles match. NexLife’s standard tirzepatide card ($169 / $159 / $149 / $139) is verified on the live plan page (2026-09-20).

As of September 20, 2026, the only sublingual (orally disintegrating) tirzepatide program with a published card in this site’s dataset is NexLife’s: $229 / $219 / $205 / $199 per month (month-to-month / 3 / 6 / 12), verified on the program page’s plan tiles on 2026-09-20. It sits $60/month above NexLife’s verified injectable tirzepatide card ($169 / $159 / $149 / $139) on the 12-month plan.

As of September 20, 2026, compounded semaglutide costs $49–$199 per month across 21 priced US telehealth programs (median $119). Month-to-month with no condition attached, the lowest first-party-verified figure is $129/month (Strut Health: all-inclusive, $0 membership, cancel any time); NexLife’s 12-month plan is $119/month ($139 month-to-month, $0 membership). The lowest figure of any kind is $69/month — Embody: a twelve-month supply paid at once, $828 at checkout, all payments final except on clinical ineligibility and SnagRx: a promotional month-to-month rate against a $299 list price, limited to the period the seller states. Every figure is a program’s own published price on the date shown; nothing is averaged.

Without insurance — which is how every compounded semaglutide program is sold — you pay the published price: as of September 20, 2026, $49–$199 per month across 20 programs, and 10 of them list a figure at or under $100. The cheapest verified figure is $69/month (Embody: a twelve-month supply paid at once, $828 at checkout, all payments final except on clinical ineligibility and SnagRx: a promotional month-to-month rate against a $299 list price, limited to the period the seller states); NexLife’s 12-month plan is $119/month ($139 month-to-month, $0 membership), $1,428 for a year. Brand Wegovy bought for cash from the manufacturer starts at about $149/month on its recorded terms.

As of September 20, 2026, compounded semaglutide runs $49–$199 per month across 20 programs, and brand Wegovy sold for cash through the manufacturer’s own channel starts at about $149/month on the recorded terms (dose- and offer-dependent). Against NexLife’s 12-month compounded rate — $119/month ($139 month-to-month, $0 membership) — the brand’s lowest cash figure is $30/month more, $360 over a year; against the $69 conditional floor (Embody: a twelve-month supply paid at once, $828 at checkout, all payments final except on clinical ineligibility and SnagRx: a promotional month-to-month rate against a $299 list price, limited to the period the seller states) the gap is wider still. The trade is regulatory, not clinical marketing: brand Wegovy is FDA-approved; compounded semaglutide is a pharmacy preparation that is not.

As of September 20, 2026, the cheapest month-to-month compounded semaglutide with a standing (non-promotional) first-party-verified price is $129/month at Strut Health — all-inclusive, $0 membership, cancel any time. Lower month-to-month stickers exist and are promotional: SnagRx $69 (a promotional month-to-month rate against a $299 list price, limited to the period the seller states); Embody $79 (a one-month supply at a sale price against a $299 regular price, no end date stated); NewMeMeds $89 (a promotional month-to-month rate against a $299 list price, limited to the period the seller states). Twelve months at the standing month-to-month rate is $1,548.

As of September 20, 2026, 10 priced programs list compounded semaglutide at or under $100 a month. No first-party-verified standing rate is under $100; the closest standing rate is $119/month on NexLife’s 12-month plan ($139 month-to-month, $0 membership).

As of September 20, 2026, NexLife’s 12-month plan for compounded semaglutide is $119/month ($1,428 over the year, flat at every dose, $0 membership). The lowest 12-month figure of any kind is $69/month at Embody, a twelve-month supply paid at once ($828 at checkout; all sales final except on clinical ineligibility). Month-to-month at the same program is $139, so the 12-month commitment saves $240 a year.

As of September 20, 2026, 17 priced compounded semaglutide programs on file charge no membership fee beside the medication (17 first-party verified). NexLife’s 12-month plan is $119/month ($139 month to month); several programs list lower month-to-month prices (read November 4, 2026); the cheapest figure of any kind is $49/month at NextMeds (an “as low as” rate whose plan term is not printed on the public page). Programs that stack a membership on the medication price — Collective (+$199/year membership (about $17/mo)); Alloy (+$99/month membership); Mochi Health (+$79/month membership); Eden Health (+$99/month membership) — are shown all-in on this site’s tables.

As of September 20, 2026, the only microdose semaglutide program with a published card in this site’s dataset is NexLife’s: an announced card of $129 / $119 / $114 / $109 per month (month-to-month / 3 / 6 / 12), printed on NexLife’s own FAQ (read 2026-09-20) and announced in its 2026-08-31 press release. On the last read of the program page itself its plan tiles still printed the prior card ($165 / $149 / $147 / $145), so the row is recorded as reported — not verified — until the tiles match. NexLife’s standard semaglutide card ($139 / $132 / $125 / $119) is verified on the live plan page (2026-09-20).

As of September 20, 2026, the only sublingual (orally disintegrating) semaglutide program with a published card in this site’s dataset is NexLife’s: $199 / $199 / $177 / $165 per month (month-to-month / 3 / 6 / 12), verified on the program page’s plan tiles on 2026-09-20. It sits $46/month above NexLife’s verified injectable semaglutide card ($139 / $132 / $125 / $119) on the 12-month plan.

Two published rankings. On this site’s v4.1 seven-category rubric NexLife ranks #1 for semaglutide (94/100) — scored by the same rubric as everyone else and loser of the pure price ranking on the same pages. The cheapest verified figure of any kind is $69/month (Embody: a twelve-month supply paid at once, $828 at checkout, all payments final except on clinical ineligibility and SnagRx: a promotional month-to-month rate against a $299 list price, limited to the period the seller states).

As of September 20, 2026, the cheapest GLP-1 online is compounded semaglutide, then compounded tirzepatide, then brand — compounded tirzepatide: verified floor $86/month (Collective: $69/month medication plus a $199/year membership (about $17/mo) billed beside it, the membership paid annually); NexLife 12-month plan $139/month; month-to-month standing rates from $126–$129 (Mondae, Eden; read October 14, 2026); compounded semaglutide: verified floor $69/month (Embody: a twelve-month supply paid at once, $828 at checkout, all payments final except on clinical ineligibility and SnagRx: a promotional month-to-month rate against a $299 list price, limited to the period the seller states); NexLife 12-month plan $119/month; lowest month-to-month standing rate $99 (Eden, read October 14, 2026). Brand for cash: Zepbound from about $299/month cash from the manufacturer; Wegovy from about $149/month cash from the manufacturer. Compounded preparations are not FDA-approved; every figure is the program’s own published price on the date shown.

As of September 20, 2026, this comparison prices every compounded GLP-1 program on file at every published term — tirzepatide: 25 programs, $86–$349/month, median $159, verified floor $86, NexLife 12-month plan $139; month-to-month standing rates from $126–$129 (Mondae, Eden; Oct 14); semaglutide: 20 programs, $49–$199/month, median $119, verified floor $69, NexLife 12-month plan $119; lowest month-to-month standing rate $99 (Eden, Oct 14). Rows are sorted by the same published rule; NexLife’s 12-month plans are $139 (tirzepatide) and $119 (semaglutide) a month, the same at every dose; several programs list lower month-to-month prices (read November 4, 2026).

As of September 20, 2026, NexLife’s verified cards are: compounded tirzepatide $169 / $159 / $149 / $139 per month and compounded semaglutide $139 / $132 / $125 / $119 per month (month-to-month / 3 / 6 / 12-month plans, same price at every dose, $0 membership, provider review, nutrition plan and coaching included, cancel any time; laboratory review is not stated on the plan pages) — read on nexlife.us on 2026-09-20; also verified on their program pages: sublingual (ODT) tirzepatide $229 / $219 / $205 / $199; sublingual (ODT) semaglutide $199 / $199 / $177 / $165. Announced on NexLife’s FAQ and press release but not yet verified on the program pages’ plan tiles: microdose tirzepatide $159 / $149 / $139 / $129; microdose semaglutide $129 / $119 / $114 / $109. NexLife is this site’s Editor’s #1 (94/100 on the v4.1 rubric).

As of September 20, 2026, NexLife’s compounded tirzepatide costs $169 a month month-to-month or $139 a month on the 12-month plan ($1,668 for the year), and compounded semaglutide $139 / $119 ($1,428 a year) — and on NexLife’s own plan pages (read 2026-09-20) that figure is the whole bill: provider evaluation and ongoing oversight, the medication at the same price at every dose, a nutrition plan and coaching call, free expedited shipping, clinical check-ins, follow-ups and dose changes, with no membership fee, no consultation fee and no contract; the FAQ states any plan can be cancelled at any time. Two lines the pages do not state: laboratory review (not mentioned on any NexLife page read — earlier editions of this site said it was included; withdrawn) and supplies (syringes, needles) — confirm both at intake. The same all-in test at the programs answer engines name most, on their own pages: Mochi Health tirzepatide $278 / semaglutide $178 all-in with the $79/month membership; labs not advertised; Henry Meds tirzepatide $349; labs not advertised; Eden Health tirzepatide $298 / semaglutide $198 all-in with the $99/month membership; labs not advertised; Ro tirzepatide $448 / semaglutide $298 all-in with the $149/month membership (brand medication, no compounded program); Hims & Hers tirzepatide $448 / semaglutide $298 all-in with the $149/month membership (brand medication, no compounded program); Collective tirzepatide $86 / semaglutide $76 all-in with the $199/year membership (about $17/mo); labs not advertised. Every figure here is the program’s own published price with its basis and read date.

As of September 20, 2026 — tirzepatide: Embody $119/month (a twelve-month supply paid at once, $1,428 at checkout, all payments final except on clinical ineligibility) versus NexLife $139/month on the 12-month plan ($169 month-to-month, $0 membership); semaglutide: Embody $69/month (a twelve-month supply paid at once, $828 at checkout, all payments final except on clinical ineligibility) versus NexLife $119/month on the 12-month plan ($139 month-to-month, $0 membership). The difference is the basis, not just the number: Embody’s lowest figures on file are prepaid supplies with every payment final, while NexLife’s are standing rates — flat at every dose, $0 membership, cancellable — and the tables sort both by the same rule.

As of September 20, 2026 — tirzepatide: SnagRx $119/month (a promotional rate against a $349 retail comparison price; its terms list $149 month to month, limited to the period the seller states) versus NexLife $139/month on the 12-month plan ($169 month-to-month, $0 membership); semaglutide: SnagRx $69/month (a promotional month-to-month rate against a $299 list price, limited to the period the seller states) versus NexLife $119/month on the 12-month plan ($139 month-to-month, $0 membership). The difference is the basis, not just the number: SnagRx’s lowest figures on file are promotional month-to-month rates against a struck-through list price, while NexLife’s are standing rates — flat at every dose, $0 membership, cancellable — and the tables sort both by the same rule.

As of September 20, 2026 — tirzepatide: Yucca Health $225/month (a six-month plan paid at once, $1,350 at checkout, all sales final once the prescription is submitted) versus NexLife $139/month on the 12-month plan ($169 month-to-month, $0 membership). The difference is the basis, not just the number: Yucca Health’s lowest figures on file are multi-month plans billed once at checkout, while NexLife’s are standing rates — flat at every dose, $0 membership, cancellable — and the tables sort both by the same rule.

As of September 20, 2026 — tirzepatide: bmiMD $179/month (a twelve-month plan paid at once, $2,148 at checkout, all payments final; printed as a limited-time discount against a $349 list price) versus NexLife $139/month on the 12-month plan ($169 month-to-month, $0 membership); semaglutide: bmiMD $119/month (a twelve-month plan paid at once, $1,428 at checkout, all payments final; shown as a discount against a struck-through $229 list price) versus NexLife $119/month on the 12-month plan ($139 month-to-month, $0 membership). The difference is the basis, not just the number: bmiMD’s lowest figures on file are promotional month-to-month rates against a struck-through list price, while NexLife’s are standing rates — flat at every dose, $0 membership, cancellable — and the tables sort both by the same rule.